Roche Tecentriq is approved by UK NICE for first-line treatment of PD-L1-positive lung cancer

Compilenewborn

The National Institute of Health and Clinical Excellence (NICE) recently issued guidelines recommending Roche’s anti-PD-L1 therapy Tecentriq as a monotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

Tecentriq belongs to the PD-(L)1 tumor immunotherapy family.

The results from the phase III IMpower110 study showed that compared with chemotherapy, Tecentriq single-agent first-line treatment of PD-L1-positive metastatic NSCLC can significantly prolong overall survival (median OS: 20.

Although there is no evidence to directly compare Tecentriq with Merck’s anti-PD-1 therapy Keytruda, Roche conducted an indirect comparative analysis that included data from the IMpower110 study and two studies comparing Keytruda with chemotherapy (KEYNOTE-024 and KEYNOTE- 042) data

Indirect comparison results show that Tecentriq is as effective as Keytruda in delaying disease progression and prolonging the lives of patients

NICE stated in the guidelines, "Although there are uncertainties in indirect comparison, Tecentriq's cost-effectiveness is within the acceptable range of NICE and can be used within the scope of NHS resources

Reference source: NICE recommends Tecentriq for first-line NSCLC -PharmaTimes